• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.

    Heplisav-B is specifically indicated for prevention of infection caused by all known subtypes of hepatitis B virus for use in adults 18 years of age and older. 

    Heplisav-B is supplied as a solution for intramuscular injection. The recommended dose is two doses (0.5 mL each) administered one month apart.

    Clinical Results

    FDA Approval

    The FDA approval of Heplisav-B was based on data from three Phase III non-inferiority trials of nearly 10,000 adults who received Hpelisav-B. The pivotal studies compared Heplisav-B administered in two doses over one month to Engerix-B administered in three doses over a six-month schedule. Results from the largest Phase III trial, which included 6,665 subjects, showed that Heplisav-B demonstrated a statistically significantly higher rate of protection of 95% compared with 81% for Engerix-B. In a subgroup analysis of 961 subjects with type II diabetes, Heplisav-B demonstrated a statistically significantly higher rate of protection of 90% compared to 65% for Engerix-B. 

    Side Effects

    Adverse effects associated with the use of Heplisav-B may include, but are not limited to, the following:

    • injection site pain
    • fatigue
    • headache

    Mechanism of Action

    Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] combines hepatitis B surface antigen with a proprietary Toll-like Receptor 9 agonist to enhance the immune response.

    Additional Information

    For additional information regarding Heplisav-B or the prevention of hepatitis B, please visit http://heplisavb.com/

    Approval Date: 2017-11-01
    Company Name: Dynavax
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • tablet

      Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

    • Diversity-360x240.png

      Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing